Lupin Limited has informed the Exchange about U.S. FDA has conducted an inspection of Company s Injectable facility at Nagpur.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin Limited has informed the stock exchange that the U.S. FDA has conducted an inspection at the company's Injectable manufacturing facility in Nagpur. The announcement does not specify the outcome of the inspection. FDA inspections at pharmaceutical facilities are routine regulatory checks covering manufacturing practices and product quality standards. Investors will need to await any follow-up communication regarding the inspection results, such as the issuance of a Form 483 or a warning letter.
No immediate impact on the stock or shareholders — this is a routine inspection notice. Investors should watch for the inspection outcome, as any adverse findings could affect U.S. approvals and future revenue from the Injectables segment.